(Q36540561)

14 August 2017

1 reference

title

Treatment of chronic myeloid leukemia with imatinib mesylate (English)

1 reference

14 August 2017

chronic myeloid leukemia

0 references

1 reference

Ryuzo Ohno

1

1 reference

14 August 2017

1 June 2006

1 reference

International Journal of Clinical Oncology

14 August 2017

1 reference

14 August 2017

11

1 reference

14 August 2017

176-183

1 reference

14 August 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1007/s10147-006-0582-5

14 August 2017

0 references

cites work

Loss of response to imatinib: mechanisms and management

1 reference

12 December 2020

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

1 reference

12 December 2020

Multicenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia. Kouseisho Leukemia Study Group

1 reference

12 December 2020

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

1 reference

12 December 2020

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

12 December 2020

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

1 reference

12 December 2020

The molecular biology of chronic myeloid leukemia.

1 reference

12 December 2020

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

1 reference

12 December 2020

Chronic myelogenous leukemia: a review and update of therapeutic strategies

1 reference

12 December 2020

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

1 reference

12 December 2020

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

1 reference

12 December 2020

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

12 December 2020

Management of early stage disease

1 reference

12 December 2020

Chronic myeloid leukemia

1 reference

12 December 2020

Chronic myeloid leukemia: a model for oncology

1 reference

12 December 2020

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

1 reference

12 December 2020

Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study

1 reference

12 December 2020

Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients

1 reference

12 December 2020

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

12 December 2020

Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service

1 reference

12 December 2020

Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia

1 reference

12 December 2020

Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data

1 reference

12 December 2020

Residual Disease in Chronic Myeloid Leukemia after Induction of Molecular Remission

1 reference

12 December 2020

Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group

1 reference

12 December 2020

Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia

1 reference

12 December 2020

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

12 December 2020

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

12 December 2020

The biology of chronic myeloid leukemia

1 reference

12 December 2020

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

1 reference

12 December 2020

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

1 reference

12 December 2020

Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies

1 reference

12 December 2020

Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib

1 reference

12 December 2020

Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study Group.

1 reference

12 December 2020

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

1 reference

12 December 2020

High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group

1 reference

12 December 2020

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia

1 reference

12 December 2020

Current trends in hematopoietic stem cell transplantation in Europe

1 reference

12 December 2020

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

1 reference

12 December 2020

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

12 December 2020

Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia

1 reference

12 December 2020

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

1 reference

12 December 2020

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

12 December 2020

Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia

1 reference

12 December 2020

Natural history and staging of chronic myelogenous leukemia

1 reference

12 December 2020

Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea

1 reference

12 December 2020

Discontinuation of imatinib therapy after achieving a molecular response

1 reference

12 December 2020

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

12 December 2020

Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia

1 reference

12 December 2020

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

12 December 2020

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

12 December 2020

Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha

1 reference

12 December 2020

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

1 reference

12 December 2020

Efficacy and safety of imatinib mesylate for patients in the first chronic phase of chronic myeloid leukemia: results of a Japanese phase II clinical study

1 reference

12 December 2020

A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase

1 reference

12 December 2020

Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study

1 reference

12 December 2020

10.1007/S10147-006-0582-5

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16850123